A House subcommittee approved a package of bills to overhaul drug-safety laws and give the FDA additional powers to require studies, limit distribution or order label changes for drugs on the market. The panel also replaced language that would have allowed the health secretary to ban new drug ads on television with a provision allowing the FDA to fine companies $250,000 for showing false or misleading ads directed at consumers.

Related Summaries